The Pharmacology of mTOR Inhibition
Top Cited Papers
- 21 April 2009
- journal article
- perspective
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 2 (67), pe24
- https://doi.org/10.1126/scisignal.267pe24
Abstract
A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)–based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.This publication has 35 references indexed in Scilit:
- Optimal targeting of the mTORC1 kinase in human cancerCurrent Opinion in Cell Biology, 2009
- PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.Cell Cycle, 2009
- A complex interplay between Akt, TSC2 and the two mTOR complexesBiochemical Society Transactions, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Regulation of TORC1 by Rag GTPases in nutrient responseNature, 2008
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1Science, 2008
- Expanding mTOR signalingCell Research, 2007
- Defining the Role of mTOR in CancerCancer Cell, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- The Tuberous Sclerosis Protein TSC2 Is Not Required for the Regulation of the Mammalian Target of Rapamycin by Amino Acids and Certain Cellular StressesPublished by Elsevier BV ,2005